BIOMAT Database Logo BIOMAT Database Logo

Long-term evolution of humoral immune response after SARS-CoV-2 infection. 2022

Elisa Teyssou, and Karen Zafilaza, and Sophie Sayon, and Stéphane Marot, and Margot Dropy, and Cathia Soulie, and Basma Abdi, and Florence Tubach, and Pierre Hausfater, and Anne-Geneviève Marcelin, and David Boutolleau, and
Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Paris, France; Sorbonne Université, Hôpital Pitié-Salpêtrière, Service de virologie, Paris, France. Electronic address: elisa.teyssou@aphp.fr.

OBJECTIVE We aimed to characterize the evolution of humoral immune response up to 1 year after SARS-CoV-2 infection in healthcare workers (HCWs) during the first wave of COVID-19 in Paris. METHODS Serum samples from 92 HCWs were tested at month 0 (M0), M6, and M12 after SARS-CoV-2 infection for IgG targeting the nucleocapsid (N), IgG targeting the receptor-binding domain (RBD) of spike (S) protein, IgA targeting S, and anti-RBD neutralizing antibodies. After M6, 46 HCWs received a single dose of COVID-19 vaccine. RESULTS We observed a significant decrease in all SARS-CoV-2 immunologic markers at M6 post-infection: median decreases were 0.26 log binding antibody units/mL (M0: 1.9 (interquartile range (IQR) 1.47-2.27); M6: 1.64 (IQR 1.22-1.92)) for anti-RBD IgG; 4.10 (index) (M0: 4.94 (IQR 2.72-6.82); M6: 0.84 (IQR 0.25-1.55)) for anti-N IgG; 0.64 (index) (M0: 2.50 (IQR 1.18-4.62); M6: 1.86 (IQR 0.85-3.54)) for anti-S IgA; and 24.4% (M0: 66.4 (IQR 39.7-82.5); M6: 42.0 (IQR 16.8-68.8)) inhibition activity for the RBD neutralizing antibodies. Between M6 and M12, anti-RBD IgG level, anti-S IgA index, and anti-RBD neutralizing activity significantly increased among COVID-19 vaccinated HCWs, whereas they remained stable among unvaccinated HCWs. Anti-N IgG index significantly decreased between M6 and M12 among both vaccinated (median: 0.73 (IQR 0.23-1.11) at M6 and 0.52 (IQR 0.20-0.73) at M12) and unvaccinated HCWs (median: 0.79 (IQR 0.21-4.67) at M6 and 0.34 (IQR 0.24-2.78) at M12). CONCLUSIONS A steady decline in the anti-N IgG response was observed during the first year after SARS-CoV-2 infection among HCWs, whereas the anti-RBD IgG and the anti-S IgA responses remained stable and could be enhanced by COVID-19 vaccination.

UI MeSH Term Description Entries
D007070 Immunoglobulin A Represents 15-20% of the human serum immunoglobulins, mostly as the 4-chain polymer in humans or dimer in other mammals. Secretory IgA (IMMUNOGLOBULIN A, SECRETORY) is the main immunoglobulin in secretions. IgA,IgA Antibody,IgA1,IgA2,Antibody, IgA
D007074 Immunoglobulin G The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B. Gamma Globulin, 7S,IgG,IgG Antibody,Allerglobuline,IgG(T),IgG1,IgG2,IgG2A,IgG2B,IgG3,IgG4,Immunoglobulin GT,Polyglobin,7S Gamma Globulin,Antibody, IgG,GT, Immunoglobulin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000086382 COVID-19 A viral disorder generally characterized by high FEVER; COUGH; DYSPNEA; CHILLS; PERSISTENT TREMOR; MUSCLE PAIN; HEADACHE; SORE THROAT; a new loss of taste and/or smell (see AGEUSIA and ANOSMIA) and other symptoms of a VIRAL PNEUMONIA. In severe cases, a myriad of coagulopathy associated symptoms often correlating with COVID-19 severity is seen (e.g., BLOOD COAGULATION; THROMBOSIS; ACUTE RESPIRATORY DISTRESS SYNDROME; SEIZURES; HEART ATTACK; STROKE; multiple CEREBRAL INFARCTIONS; KIDNEY FAILURE; catastrophic ANTIPHOSPHOLIPID ANTIBODY SYNDROME and/or DISSEMINATED INTRAVASCULAR COAGULATION). In younger patients, rare inflammatory syndromes are sometimes associated with COVID-19 (e.g., atypical KAWASAKI SYNDROME; TOXIC SHOCK SYNDROME; pediatric multisystem inflammatory disease; and CYTOKINE STORM SYNDROME). A coronavirus, SARS-CoV-2, in the genus BETACORONAVIRUS is the causative agent. 2019 Novel Coronavirus Disease,2019 Novel Coronavirus Infection,2019-nCoV Disease,2019-nCoV Infection,COVID-19 Pandemic,COVID-19 Pandemics,COVID-19 Virus Disease,COVID-19 Virus Infection,Coronavirus Disease 2019,Coronavirus Disease-19,SARS Coronavirus 2 Infection,SARS-CoV-2 Infection,Severe Acute Respiratory Syndrome Coronavirus 2 Infection,COVID19,2019 nCoV Disease,2019 nCoV Infection,2019-nCoV Diseases,2019-nCoV Infections,COVID 19,COVID 19 Pandemic,COVID 19 Virus Disease,COVID 19 Virus Infection,COVID-19 Virus Diseases,COVID-19 Virus Infections,Coronavirus Disease 19,Disease 2019, Coronavirus,Disease, 2019-nCoV,Disease, COVID-19 Virus,Infection, 2019-nCoV,Infection, COVID-19 Virus,Infection, SARS-CoV-2,Pandemic, COVID-19,SARS CoV 2 Infection,SARS-CoV-2 Infections,Virus Disease, COVID-19,Virus Infection, COVID-19
D000086402 SARS-CoV-2 A species of BETACORONAVIRUS causing atypical respiratory disease (COVID-19) in humans. The organism was first identified in 2019 in Wuhan, China. The natural host is the Chinese intermediate horseshoe bat, RHINOLOPHUS affinis. 2019 Novel Coronavirus,COVID-19 Virus,COVID19 Virus,Coronavirus Disease 2019 Virus,SARS Coronavirus 2,SARS-CoV-2 Virus,Severe Acute Respiratory Syndrome Coronavirus 2,Wuhan Coronavirus,Wuhan Seafood Market Pneumonia Virus,2019-nCoV,2019 Novel Coronaviruses,COVID 19 Virus,COVID-19 Viruses,COVID19 Viruses,Coronavirus 2, SARS,Coronavirus, 2019 Novel,Coronavirus, Wuhan,Novel Coronavirus, 2019,SARS CoV 2 Virus,SARS-CoV-2 Viruses,Virus, COVID-19,Virus, COVID19,Virus, SARS-CoV-2,Viruses, COVID19
D000086663 COVID-19 Vaccines Vaccines or candidate vaccines containing SARS-CoV-2 component antigens, genetic materials, or inactivated SARS-CoV-2 virus, and designed to prevent COVID-19. 2019 Novel Coronavirus Vaccine,2019 Novel Coronavirus Vaccines,2019-nCoV Vaccine,2019-nCoV Vaccines,COVID 19 Vaccine,COVID-19 Vaccine,COVID-19 Virus Vaccine,COVID-19 Virus Vaccines,COVID19 Vaccine,COVID19 Vaccines,COVID19 Virus Vaccine,COVID19 Virus Vaccines,Coronavirus Disease 2019 Vaccine,Coronavirus Disease 2019 Vaccines,Coronavirus Disease 2019 Virus Vaccine,Coronavirus Disease 2019 Virus Vaccines,Coronavirus Disease-19 Vaccine,Coronavirus Disease-19 Vaccines,SARS Coronavirus 2 Vaccines,SARS-CoV-2 Vaccine,SARS-CoV-2 Vaccines,SARS2 Vaccine,SARS2 Vaccines,2019 nCoV Vaccine,2019 nCoV Vaccines,COVID 19 Vaccines,COVID 19 Virus Vaccine,COVID 19 Virus Vaccines,Coronavirus Disease 19 Vaccine,Coronavirus Disease 19 Vaccines,SARS CoV 2 Vaccine,SARS CoV 2 Vaccines,Vaccine, 2019-nCoV,Vaccine, COVID 19,Vaccine, COVID-19,Vaccine, COVID-19 Virus,Vaccine, COVID19,Vaccine, COVID19 Virus,Vaccine, Coronavirus Disease-19,Vaccine, SARS-CoV-2,Vaccine, SARS2,Vaccines, 2019-nCoV,Vaccines, COVID-19,Vaccines, COVID-19 Virus,Vaccines, COVID19,Vaccines, COVID19 Virus,Vaccines, Coronavirus Disease-19,Vaccines, SARS-CoV-2,Vaccines, SARS2,Virus Vaccine, COVID-19,Virus Vaccine, COVID19,Virus Vaccines, COVID-19,Virus Vaccines, COVID19
D000914 Antibodies, Viral Immunoglobulins produced in response to VIRAL ANTIGENS. Viral Antibodies
D056724 Immunity, Humoral Antibody-mediated immune response. Humoral immunity is brought about by ANTIBODY FORMATION, resulting from TH2 CELLS activating B-LYMPHOCYTES, followed by COMPLEMENT ACTIVATION. Humoral Immune Response,Humoral Immune Responses,Humoral Immunity,Immune Response, Humoral,Immune Responses, Humoral,Response, Humoral Immune
D057134 Antibodies, Neutralizing Antibodies that reduce or abolish some biological activity of a soluble antigen or infectious agent, usually a virus. Neutralizing Antibodies,Antibody, Neutralizing,Neutralizing Antibody

Related Publications

Elisa Teyssou, and Karen Zafilaza, and Sophie Sayon, and Stéphane Marot, and Margot Dropy, and Cathia Soulie, and Basma Abdi, and Florence Tubach, and Pierre Hausfater, and Anne-Geneviève Marcelin, and David Boutolleau, and
Long-Term Humoral Immune Response in Persons with Asymptomatic or Mild SARS-CoV-2 Infection, Vietnam.
February 2021, Emerging infectious diseases,
Elisa Teyssou, and Karen Zafilaza, and Sophie Sayon, and Stéphane Marot, and Margot Dropy, and Cathia Soulie, and Basma Abdi, and Florence Tubach, and Pierre Hausfater, and Anne-Geneviève Marcelin, and David Boutolleau, and
Long-Term Course of Humoral and Cellular Immune Responses in Outpatients After SARS-CoV-2 Infection.
January 2021, Frontiers in public health,
Elisa Teyssou, and Karen Zafilaza, and Sophie Sayon, and Stéphane Marot, and Margot Dropy, and Cathia Soulie, and Basma Abdi, and Florence Tubach, and Pierre Hausfater, and Anne-Geneviève Marcelin, and David Boutolleau, and
Humoral Immune Response to SARS-CoV-2.
October 2020, American journal of clinical pathology,
Elisa Teyssou, and Karen Zafilaza, and Sophie Sayon, and Stéphane Marot, and Margot Dropy, and Cathia Soulie, and Basma Abdi, and Florence Tubach, and Pierre Hausfater, and Anne-Geneviève Marcelin, and David Boutolleau, and
Long-term Immune Response to SARS-CoV-2 Infection Among Children and Adults After Mild Infection.
July 2022, JAMA network open,
Elisa Teyssou, and Karen Zafilaza, and Sophie Sayon, and Stéphane Marot, and Margot Dropy, and Cathia Soulie, and Basma Abdi, and Florence Tubach, and Pierre Hausfater, and Anne-Geneviève Marcelin, and David Boutolleau, and
Humoral immune response after different SARS-CoV-2 vaccination regimens.
January 2022, BMC medicine,
Elisa Teyssou, and Karen Zafilaza, and Sophie Sayon, and Stéphane Marot, and Margot Dropy, and Cathia Soulie, and Basma Abdi, and Florence Tubach, and Pierre Hausfater, and Anne-Geneviève Marcelin, and David Boutolleau, and
Impact of hypertension on long-term humoral and cellular response to SARS-CoV-2 infection.
January 2022, Frontiers in immunology,
Elisa Teyssou, and Karen Zafilaza, and Sophie Sayon, and Stéphane Marot, and Margot Dropy, and Cathia Soulie, and Basma Abdi, and Florence Tubach, and Pierre Hausfater, and Anne-Geneviève Marcelin, and David Boutolleau, and
Persistence of humoral and cellular immune response after SARS-CoV-2 infection: opportunities and challenges.
December 2020, Frontiers of medicine,
Elisa Teyssou, and Karen Zafilaza, and Sophie Sayon, and Stéphane Marot, and Margot Dropy, and Cathia Soulie, and Basma Abdi, and Florence Tubach, and Pierre Hausfater, and Anne-Geneviève Marcelin, and David Boutolleau, and
Humoral Immune Response of SARS-CoV-2 Infection and Anti-SARS-CoV-2 Vaccination in Renal Transplant Recipients.
March 2022, Vaccines,
Elisa Teyssou, and Karen Zafilaza, and Sophie Sayon, and Stéphane Marot, and Margot Dropy, and Cathia Soulie, and Basma Abdi, and Florence Tubach, and Pierre Hausfater, and Anne-Geneviève Marcelin, and David Boutolleau, and
Humoral Immune Response to SARS-CoV-2 in Iceland.
October 2020, The New England journal of medicine,
Elisa Teyssou, and Karen Zafilaza, and Sophie Sayon, and Stéphane Marot, and Margot Dropy, and Cathia Soulie, and Basma Abdi, and Florence Tubach, and Pierre Hausfater, and Anne-Geneviève Marcelin, and David Boutolleau, and
Long-term perturbation of the peripheral immune system months after SARS-CoV-2 infection.
January 2022, BMC medicine,
Copied contents to your clipboard!